Journals on Medical Science - BJSTR Journal

Abstract

#Pancreatic cancer is currently one of the deadliest of the #solid malignancies and has a particularly low survival rate in the future because targeted therapies for other cancers are becoming more advanced than those for pancreatic cancer [1]. The optimal treatment first and foremost depends on careful accurate staging. The American Joint Committee on Cancer (AJCC) staging system, which includes the TNM classification, is the most widely used system to stage #pancreatic cancer [2]. Patients with Stage I/II disease should undergo surgical resection followed by adjuvant therapy, while patients with Stage III borderline resectable cancers should undergo neoadjuvant therapy prior to resection. Patients with stage III locally advanced disease should be treated with chemotherapy and/or #chemoradiotherapy. Patients with Stage IV and good performance status may receive systemic therapy and those with poor overall health should be given supportive therapy [3]. A meta-analysis of trials performed between 1970 and 2003 demonstrated that 5-FU was superior to best supportive care [4]. But in 1997 a randomized phase III trial demonstrated a survival benefit for #gemcitabine over bolus 5-FU with a median survival of 5.65 months as compared to 4.41 months, and 1-year survivals of 18% versus 2%. Gemcitabine had a superior clinical benefit response described as improvement in pain, performance status or weight in 24% of the patients versus 5% in the 5-FU group. Based on this trial, gemcitabine was approved by the Food and Drug Administration for pancreatic cancer and gemcitabine became the standard of care [5]. From then on, a lot of gemcitabine-based combinations have been tested [6]. Gemcitabine plus oxaliplatin or #cisplatin showed no statistically significant improvement in survival in phase III trials [7-8]. A phase I/II trial published in 2011 demonstrated exciting results when gemcitabine was combined with nab-paclitaxel as first-line therapy for metastatic pancreatic cancer patients [9]. 

For more articles on BJSTR Journal please click on https://biomedres.us/ 

For more Medical Science Articles on BJSTR 

https://biomedres.us/fulltexts/BJSTR.MS.ID.001860.php

The Human Equilibrative Nucleoside Transporter Protein1 (Hent1) is a Predict /Prognostic Factor in Resected Pancreatic Cancer Patients by Li Xiao Rui in BJSTR

Follow on Twitter : https://twitter.com/Biomedres01

Follow on Tumbler: https://biomedres.tumblr.com/

Like Our Pins On : https://www.pinterest.com/biomedres/